Tavilermide

Tavilermide
Clinical data
Routes of; administration	Eye drop
ATC code	None;
Identifiers
	IUPAC name 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid;
CAS Number	263251-78-1;
PubChem CID	9808372;
ChemSpider	7984131;
CompTox Dashboard (EPA)	DTXSID00180937 ;
Chemical and physical data
Formula	C24H32N6O11
Molar mass	580.54448 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O;
	InChI InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1; Key:DVJXNXPFYJIACK-ULQDDVLXSA-N;

Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.^[1]^[2]^[3] It is under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and is in phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.[1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.^[4][2]

References

^ Meerovitch, Karen; Torkildsen, Gail; Lonsdale, John; Goldfarb, Heidi; Lama, Teresa; Cumberlidge, Garth; Ousler III, George W. (2013). "Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye". Clinical Ophthalmology: 1275. doi:10.2147/OPTH.S44688. ISSN 1177-5483.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Jain, Pooja; Li, Ruihong; Lama, Teresa; Saragovi, H. Uri; Cumberlidge, Garth; Meerovitch, Karen (2011). "An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye". Experimental Eye Research. 93 (4): 503–512. doi:10.1016/j.exer.2011.06.014. ISSN 0014-4835.
^ Vickers, Laura A.; Gupta, Preeya K. (2015). "The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline". Ophthalmology and Therapy. doi:10.1007/s40123-015-0038-y. ISSN 2193-8245.
^ Chang EE, Goldberg JL (2012). "Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement". Ophthalmology. 119 (5): 979–86. doi:10.1016/j.ophtha.2011.11.003. PMC 3343191. PMID 22349567.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.